$2.30
8.73% day before yesterday
Nasdaq, Jul 11, 10:00 pm CET
ISIN
US49720K1016
Symbol
HURA
Sector
Industry

Kintara Therapeutics Inc Stock price

$2.30
-0.36 13.53% 1M
-2.01 46.64% 6M
-1.79 43.77% YTD
-2.48 51.93% 1Y
-224.15 98.98% 3Y
-606.79 99.62% 5Y
-20,647.70 99.99% 10Y
-1,546.45 99.85% 20Y
Nasdaq, Closing price Fri, Jul 11 2025
-0.22 8.73%
ISIN
US49720K1016
Symbol
HURA
Sector
Industry

Key metrics

Basic
Market capitalization
$107.1m
Enterprise Value
$100.8m
Net debt
positive
Cash
$6.2m
Shares outstanding
43.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
10.9
Financial Health
Equity Ratio
73.1%
Return on Equity
-155.2%
ROCE
-274.4%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-26.9m | -
EBIT
$-27.1m | $-25.6m
Net Income
$-31.6m | $-24.4m
Free Cash Flow
$-21.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-187.1% | -
EBIT
-187.4% | -45.2%
Net Income
-232.4% | -7.6%
Free Cash Flow
-189.4%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.7
FCF per Share
$-0.5
Short interest
6.4%
Employees
-
Rev per Employee
-
Show more

Is Kintara Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Kintara Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Kintara Therapeutics Inc forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Kintara Therapeutics Inc forecast:

Buy
88%
Hold
13%

Financial data from Kintara Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.03 9.03
89% 89%
-
- Research and Development Expense 18 18
288% 288%
-
-27 -27
187% 187%
-
- Depreciation and Amortization 0.15 0.15
200% 200%
-
EBIT (Operating Income) EBIT -27 -27
187% 187%
-
Net Profit -32 -32
232% 232%
-

In millions USD.

Don't miss a Thing! We will send you all news about Kintara Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kintara Therapeutics Inc Stock News

Neutral
PRNewsWire
12 days ago
TAMPA, Fla. , July 1, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that the Company has been added to the Russell 3000® Index, with automatic inclusion in the Russell 2000® Index, as a part of the 2025 Russell indexes annual ...
Neutral
PRNewsWire
13 days ago
Acquisition adds Phase 2 ready novel VISTA inhibiting monoclonal antibody (mAb) to TuHURA's late-stage immuno-oncology pipeline TuHURA planning to initiate a Phase 2 randomized trial involving VISTA inhibiting antibody in 2nd Half 2025 Completion of the acquisition unlocks the fourth tranche of funds from $12.5 million aggregate PIPE financing announced June 3, 2025 TAMPA, Fla. , June 30, 2025 ...
Neutral
PRNewsWire
19 days ago
Phase 3 trial being conducted under a Special Protocol Assessment (SPA) agreement with U.S. Food and Drug Administration (FDA) Primary endpoint of Overall Response Rate (ORR) qualifies for accelerated approval process Key secondary endpoint of Progression Free Survival (PFS) may satisfy the requirement for a post confirmatory trial, converting accelerated approval to regular approval Initiation...
More Kintara Therapeutics Inc News

Company Profile

Kintara Therapeutics, Inc. is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. Its pipeline includes the VAL-083 and REM-001. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.

Head office United States
CEO James Bianco
Founded 2009
Website tuhurabio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today